HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer
Status:
Terminated
Trial end date:
2020-03-20
Target enrollment:
Participant gender:
Summary
The prognosis of patients with unresectable peritoneal metastases from gastric cancer is
poor. These patients may obtain survival benefit from radical gastrectomy and cytoreductive
surgery (CRS). The response rates of previous conversion therapy are low. Hyperthermic
intraperitoneal chemoperfusion (HIPEC) and systemic chemotherapy are effective methods of
reducing peritoneal cancer index (PCI) levels. Apatinib, a novel targeted inhibitor of VEGF
receptor 2 (VEGFR2), shows significant antitumor activity in the patients with gastric
cancer. The purpose of this study is to investigate the efficacy and safety of HIPEC and
systemic chemotherapy combined with Apatinib in the conversion therapy of peritoneal
metastases from gastric cancer.